|
|
Biocon has entered into a strategic alliance with Amylin Pharmaceuticals of US for manufacturing peptide hybrid molecule which is used for the treatment of diabetes. Biocon has disclosed that the drug will be manufactured as collaboration between the two. The statement also reports that the costs will be shared between the two.
Focus of the research will be on Amylin's "phybrid" technology which has the potential to join two peptide hormones into a single one.
The expertise of Biocon in recombinant microbial expression will be used for manufacturing the drug. It will also employ its experiences in the pre-clinical and clinical development of these anti-diabetes products.
According to Biocon chairman and managing director Kiran Mazumdar-Shaw, the agreement leverages the synergistic capabilities of the two companies.
"Amylin's knowledge of peptide therapeutics and its leadership in the diabetes market, paired with our capabilities in process development, manufacturing and clinical development, provides ample scope to bring a novel therapy to diabetics," Shaw said in the statement.
Amylin chief executive Daniel M. Bradbury said the tie-up would lead to cutting-edge peptide science to provide relief diabetic patients.
